Two weeks of silibinin treatment could ameliorate PAH, as indicated by the downregulation of RVSP, Fulton index, % MT, VOS, and the CXCR4, SDF-1, and TNFα gene expression results. This evidence concerns the gene TNF and pulmonary arterial hypertension.